News | 17 December 2025
Bristol Myers Squibb launches AI-powered ‘Mosaic’ hub in Mumbai
India plays a critical role in Bristol Myers Squibb’s global strategy
India plays a critical role in Bristol Myers Squibb’s global strategy
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The company operates a chain of mid-sized multi-speciality hospitals
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
This launch is part of the company's strategy to expand its nutraceutical portfolio
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Clinical trial enrollment has long been a bottleneck in drug development
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
Subscribe To Our Newsletter & Stay Updated
